Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiuLMLixia MaYGYuelu Guo

Discussion

Loading...

Member takes

Overview

Retrospective study reveals CAR-T therapy improves treatment outcomes in TP53-mutant large B-cell lymphoma patients, suggesting new hope.

Key Points

  • To evaluate the prognostic significance of TP53 mutations and assess the impact of CAR-T therapy on treatment outcomes.
  • Retrospective analysis of 195 adult patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)
  • Patients classified by TP53 mutation status and treatment received into four groups
  • Next-generation sequencing conducted to assess mutation profiles
  • Treatment responses evaluated via Lugano 2014 criteria and survival analyzed using Kaplan-Meier and log-rank tests.
  • Overall objective response rate for CAR-T was 49.3%, with a complete response rate of 36.8%.
  • In TP53-mutant + CAR-T group, median overall survival was 12.13 months; progression-free survival was 6.87 months.
  • Contrastingly, median overall survival for TP53-mutant + non-CAR-T group was 1.87 months.
  • Treatment with CAR-T significantly improved overall survival in TP53-mutant patients compared to non-CAR-T options.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dec5https://doi.org/10.1182/blood-2025-3706
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma2025
  2. 2Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.2025 · 2 citations
  3. 3Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma2025
  4. 4CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier2025
  5. 5Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy2026